Phase 1/2 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC.

Authors: Joel R Hecht, Diwakar Davar, Marwan Fakih, Tanios S. Bekaii-Saab, Nicholas C. DeVito, John George Knecht, Andrae Lavon Vandross, Cesar Augusto Perez, Alberto Bessudo, Anurag Gupta, Ekta Patel, Damiano Fantini, Sattanathan Paramasivan, David Crowe, Meghan Duncan, Scott McConnell, Katarina Luptakova, Aparna Raj Parikh

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.206

Source: Full article

---

Abstract

206